Peptisource

Cagrilintide 5mg

Cagrilintide is a dual amylin and calcitonin receptor agonist (DACRA) that is engineered based on the structural framework of amylin. It functions by activating both the amylin receptor and the calcitonin receptor, thereby demonstrating the potential to modulate metabolic parameters, including body weight and blood glucose levels.The development of Cagrilintide is grounded in the physiological properties of native amylin. Amylin, a hormone secreted by pancreatic cells, plays a crucial role in inducing satiety, which subsequently leads to a reduction in food intake. Moreover, amylin contributes to the regulation of blood glucose metabolism through multiple mechanisms, such as inhibiting the postprandial release of glucagon and retarding gastric emptying.Not with standing its physiological significance, native amylin is limited in clinical application due to its relatively short half-life. To address this limitation, Cagrilintide has been developed as a long-acting analog, featuring a half-life of approximately 7 to 8 days. This extended half-life notably enhances the convenience of administration and patient compliance, offering a more practical therapeutic option.

Spec: 5mg
Packaging: 1kits（10Vials）
$160USD
1

▎Cagrilintide Overview


Cagrilintide is a dual amylin and calcitonin receptor agonist (DACRA) that is engineered based on the structural framework of amylin. It functions by activating both the amylin receptor and the calcitonin receptor, thereby demonstrating the potential to modulate metabolic parameters, including body weight and blood glucose levels.The development of Cagrilintide is grounded in the physiological properties of native amylin. Amylin, a hormone secreted by pancreatic cells, plays a crucial role in inducing satiety, which subsequently leads to a reduction in food intake. Moreover, amylin contributes to the regulation of blood glucose metabolism through multiple mechanisms, such as inhibiting the postprandial release of glucagon and retarding gastric emptying.Not with standing its physiological significance, native amylin is limited in clinical application due to its relatively short half-life. To address this limitation, Cagrilintide has been developed as a long-acting analog, featuring a half-life of approximately 7 to 8 days. This extended half-life notably enhances the convenience of administration and patient compliance, offering a more practical therapeutic option.